Skip to content Skip to footer
Subscribe Now
Viewpoints_Gunjan Sharma
VIEWPOINTS

Redefining Care: Gunjan Sharma from The US Oncology Network in Conversation with PharmaShots

Shots:  Megestrol, an appetite stimulator is listed as an inappropriate medication based on the American Geriatrics Society (AGS) Beers Criteria and is considered a high-risk medication for elderly people by the Pharmacy Quality Alliance  In a study by the US Oncology Network, the use of megestrol was reviewed and weight gain benefits was evaluated in…
July 31, 2024

Read more

Viewpoints_Tahi Ahmadi
VIEWPOINTS

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots:  Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms  Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab  With this acquisition, Genmab…
July 29, 2024

Read more

Viewpoints_Jane Chung
VIEWPOINTS

Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots

Shots:   Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF   Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta   Sutro is now enrolling patients for the…
July 24, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …
July 15, 2024

Read more

Viewpoints_Efrat Kaduri
VIEWPOINTS

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots:  Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells  Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors  While highlighting the intellectual…
July 10, 2024

Read more

ThoughtSpot_Saurabh Chaubey5
THOUGHTSPOT

4 Biopharma Trends to Watch out in 2024

Shots:  2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation  With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate  The article explores four key…
July 9, 2024

Read more

Viewpoints_Xochitl Javier
VIEWPOINTS

Redefining Technology: Xochitl Javier from Thermo Fisher Scientific in Conversation with PharmaShots

Shots:  Raman Analyzers are widely used in the biopharma industry to analyze different substances. Based on the principles of Raman Spectroscopy, Raman Analyzers provide information about their chemical composition and structure when interacting with laser  Today, at PharmaShots, we have Xochitl Javier, Director, Product Management & Marketing, Thermo Fisher Scientific, shedding light on the TruScan…
July 8, 2024

Read more

Viewpoints_Andrew Menzies-Gow
VIEWPOINTS

AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots:  AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases  Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition  Andrew stresses reducing the use…
July 3, 2024

Read more

Load more